Literature DB >> 15855508

A novel MATE family efflux pump contributes to the reduced susceptibility of laboratory-derived Staphylococcus aureus mutants to tigecycline.

Fionnuala McAleese1, Peter Petersen, Alexey Ruzin, Paul M Dunman, Ellen Murphy, Steven J Projan, Patricia A Bradford.   

Abstract

Tigecycline, an expanded-broad-spectrum glycylcycline antibiotic is not affected by the classical tetracycline resistance determinants found in Staphylococcus aureus. The in vitro selection of mutants with reduced susceptibility to tigecycline was evaluated for two methicillin-resistant S. aureus strains by serial passage in increasing concentrations of tigecycline. Both strains showed a stepwise elevation in tigecycline MIC over a period of 16 days, resulting in an increase in tigecycline MIC of 16- and 32-fold for N315 and Mu3, respectively. Transcriptional profiling revealed that both mutants exhibited over 100-fold increased expression of a gene cluster, mepRAB (multidrug export protein), encoding a MarR-like transcriptional regulator (mepR), a novel MATE family efflux pump (mepA), and a hypothetical protein of unknown function (mepB). Sequencing of the mepR gene in the mutant strains identified changes that presumably inactivated the MepR protein, which suggested that MepR functions as a repressor of mepA. Overexpression of mepA in a wild-type background caused a decrease in susceptibility to tigecycline and other substrates for MATE-type efflux pumps, although it was not sufficient to confer high-level resistance to tigecycline. Complementation of the mepR defect by overexpressing a wild-type mepR gene reduced mepA transcription and lowered the tigecycline MIC in the mutants. Transcription of tet(M) also increased by over 40-fold in the Mu3 mutant. This was attributed to a deletion in the promoter region of the gene that removed a stem-loop responsible for transcriptional attenuation. However, overexpression of the tet(M) transcript in a tigecycline-susceptible strain was not enough to significantly increase the MIC of tigecycline. These results suggest that the overexpression of mepA but not tet(M) may contribute to decreased susceptibility of tigecycline in S. aureus.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15855508      PMCID: PMC1087644          DOI: 10.1128/AAC.49.5.1865-1871.2005

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Transcription profiling-based identification of Staphylococcus aureus genes regulated by the agr and/or sarA loci.

Authors:  P M Dunman; E Murphy; S Haney; D Palacios; G Tucker-Kellogg; S Wu; E L Brown; R J Zagursky; D Shlaes; S J Projan
Journal:  J Bacteriol       Date:  2001-12       Impact factor: 3.490

2.  National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992-June 2001, issued August 2001.

Authors: 
Journal:  Am J Infect Control       Date:  2001-12       Impact factor: 2.918

3.  Whole genome sequencing of meticillin-resistant Staphylococcus aureus.

Authors:  M Kuroda; T Ohta; I Uchiyama; T Baba; H Yuzawa; I Kobayashi; L Cui; A Oguchi; K Aoki; Y Nagai; J Lian; T Ito; M Kanamori; H Matsumaru; A Maruyama; H Murakami; A Hosoyama; Y Mizutani-Ui; N K Takahashi; T Sawano; R Inoue; C Kaito; K Sekimizu; H Hirakawa; S Kuhara; S Goto; J Yabuzaki; M Kanehisa; A Yamashita; K Oshima; K Furuya; C Yoshino; T Shiba; M Hattori; N Ogasawara; H Hayashi; K Hiramatsu
Journal:  Lancet       Date:  2001-04-21       Impact factor: 79.321

4.  Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.

Authors:  P E Sum; P Petersen
Journal:  Bioorg Med Chem Lett       Date:  1999-05-17       Impact factor: 2.823

Review 5.  Regulation of bacterial drug export systems.

Authors:  Steve Grkovic; Melissa H Brown; Ronald A Skurray
Journal:  Microbiol Mol Biol Rev       Date:  2002-12       Impact factor: 11.056

6.  Preclinical pharmacology of GAR-936, a novel glycylcycline antibacterial agent.

Authors:  S J Projan
Journal:  Pharmacotherapy       Date:  2000-09       Impact factor: 4.705

7.  Evaluation of a tetracycline-inducible promoter in Staphylococcus aureus in vitro and in vivo and its application in demonstrating the role of sigB in microcolony formation.

Authors:  B T Bateman; N P Donegan; T M Jarry; M Palma; A L Cheung
Journal:  Infect Immun       Date:  2001-12       Impact factor: 3.441

8.  In vitro and in vivo activities of tigecycline (GAR-936), daptomycin, and comparative antimicrobial agents against glycopeptide-intermediate Staphylococcus aureus and other resistant gram-positive pathogens.

Authors:  Peter J Petersen; Patricia A Bradford; William J Weiss; Timothy M Murphy; P E Sum; Steven J Projan
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

9.  Staphylococcus aureus resistant to vancomycin--United States, 2002.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2002-07-05       Impact factor: 17.586

10.  Staphylococcus aureus svrA: a gene required for virulence and expression of the agr locus.

Authors:  Steve Garvis; Ji-Min Mei; Javier Ruiz-Albert; David W Holden
Journal:  Microbiology       Date:  2002-10       Impact factor: 2.777

View more
  78 in total

1.  MepR, a repressor of the Staphylococcus aureus MATE family multidrug efflux pump MepA, is a substrate-responsive regulatory protein.

Authors:  Glenn W Kaatz; Carmen E DeMarco; Susan M Seo
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

2.  sigmaB activity in a Staphylococcus aureus hemB mutant.

Authors:  Maria M Senn; Markus Bischoff; Christof von Eiff; Brigitte Berger-Bächi
Journal:  J Bacteriol       Date:  2005-11       Impact factor: 3.490

3.  Functional, biophysical, and structural bases for antibacterial activity of tigecycline.

Authors:  Matthew W Olson; Alexey Ruzin; Eric Feyfant; Thomas S Rush; John O'Connell; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Mutations at the Ribosomal S10 Gene in Clinical Strains of Staphylococcus aureus with Reduced Susceptibility to Tigecycline.

Authors:  M Angeles Argudín; S Roisin; M Dodémont; C Nonhoff; A Deplano; O Denis
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

5.  ramR mutations in clinical isolates of Klebsiella pneumoniae with reduced susceptibility to tigecycline.

Authors:  M Hentschke; M Wolters; I Sobottka; H Rohde; M Aepfelbacher
Journal:  Antimicrob Agents Chemother       Date:  2010-03-29       Impact factor: 5.191

Review 6.  Efflux-mediated drug resistance in bacteria: an update.

Authors:  Xian-Zhi Li; Hiroshi Nikaido
Journal:  Drugs       Date:  2009-08-20       Impact factor: 9.546

7.  Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline.

Authors:  María-Isabel Morosini; María García-Castillo; Teresa M Coque; Aránzazu Valverde; Angela Novais; Elena Loza; Fernando Baquero; Rafael Cantón
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

Review 8.  Xenobiotic efflux in bacteria and fungi: a genomics update.

Authors:  Ravi D Barabote; Jose Thekkiniath; Richard E Strauss; Govindsamy Vediyappan; Joe A Fralick; Michael J San Francisco
Journal:  Adv Enzymol Relat Areas Mol Biol       Date:  2011

9.  Capability of 11 antipneumococcal antibiotics to select for resistance by multistep and single-step methodologies.

Authors:  Catherine L Clark; Klaudia Kosowska-Shick; Lois M Ednie; Peter C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  2007-09-17       Impact factor: 5.191

10.  MATE transport of the E. coli-derived genotoxin colibactin.

Authors:  Jarrod J Mousa; Ye Yang; Sarah Tomkovich; Ayaka Shima; Rachel C Newsome; Prabhanshu Tripathi; Eric Oswald; Steven D Bruner; Christian Jobin
Journal:  Nat Microbiol       Date:  2016-01-11       Impact factor: 17.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.